Aims: To save time and labour in mass screening, by detecting two marker proteins on one specimen using only one test.
Interest has recently focused on the diagnosis and treatment of various concomitant diseases in the same patient. It is imperative that subclinical conditions should be detected before they become manifest. Mass screening to detect subclinical conditions in large populations therefore offers considerable promise. Most 
Methods
Horseradish peroxidase, grade I-C, RZ 31, was purchased from Toyobo Co., Japan. The N-hydroxysuccinimide ester of N-(4-carboxycyclohexylmethyl)-maleimide (CHM) was from Zieben Chemical Co., Japan. Sephadex G-25 and Sephacryl S-200 came from Pharmacia Fine Chemicals, Sweden. Other reagents were obtained from Wako, Japan.
Rabbit anti-a fetoprotein and anti-ferritin were prepared from serum samples of rabbits immunised with a fetoprotein and ferritin, respectively, in complete Freund's adjuvant. Antibodies were isolated by immunoaffinity chromatography, and F(ab')% fragments were prepared by digestion of the antibodies with pepsin.
Enzyme-labelled antibodies were prepared, as described previously.2 The carbohydrate moiety of HRP was oxidised by treating the enzyme with sodium periodate (NaIO4) using the method of Nakane and Kawaoi.3 A mixture of 2 ml of HRP treated with sodium periodate (5 mg/ml) in 1 mM sodium acetate buffer (pH 4-2) and 2 ml of 0-3M NaHCO3 containing 60 mM tetramethylenediamine was incubated for two hours at 25°C with continuous stirring to allow for the formation of the Shiff base. Then 0 1 ml of freshly prepared NaBH4 solution (4 mg/ml) was added to reduce the Shiff base. The mixture was left to stand for one hour at 4°C, dialysed against 20 mM sodium phosphate buffered saline, pH 
STANDARD PROCEDURE FOR HOMOGENEOUS ENZYME IMMUNOASSAY FOR a FETOPROTEIN AND FERRITIN
A mixture of 50 p1 of test serum and 100 p1 of HRP-labelled antibodies in PBS containing 3% polyethylene glycol 6000 (PEG) was incubated for 20 minutes at 37°C. Then 0 5 ml of PBS containing 25 mM phenol, 0-75 mM 4-aminoantipyrine, and 35 mM hydrogen peroxide was added. After incubation for 10 minutes at 37°C 2 ml of 1-8% formaldehyde in PBS was added to stop the enzyme reaction and the absorbance was measured at 500 nm (As).
As a control, the procedure was carried out with HRP-labelled normal IgG instead of HRP-labelled antibody and the absorbancy was determined (AO). The HRP activity of the test sample was expressed as A = AS -AO.
Under these conditions HRP-labelled antibody has no catalytic activity, but HRPlabelled antibody aggregates (bound with antigen) show catalytic activity.
Results

CALIBRATION CURVES FOR ASSAYS OF aX FETOPROTEIN AND FERRITIN BY ORDINARY HOMOGENEOUS EIA
Calibration curves for a fetoprotein and ferritin were made using WHO standards diluted with PBS containing 4 5% bovine serum albumin. .0 cx Fetoprotein and ferritin at concentrations of 10-800 ng/ml were determined quantitatively (fig 1) .
SIMULTANEOUS ASSAY OF a FETOPROTEIN
The cutoff values of a fetoprotein and ferritin were set at 20 ng/ml and 200 ng/ml, respectively. To reduce the contribution of ferritin to the optical density, unlabelled anti-ferritin antibody was added to the assay mixture. As shown in fig 2 240 pg/ml of anti-ferritin antibody was required to adjust the absorbance of 200 ng/ml ferritin to that of 20 ng/ml a fetoprotein.
The assay mixture for simultaneous determination of a fetoprotein and ferritin was as follows: 100 p1 of reagent containing 3% PEG, 1 jug/ml of HRP-labelled anti-ci fetoprotein, 1 pg/ml of anti-ferritin antibodies and 240 Mg/ml of unlabelled anti-ferritin in PBS were admixed with 50 p1 of sample solution. After incubating the mixture for 20 minutes at 37°C enzyme activity was measured. Healthy subjects a Fetoprotein and ferritin in 50 sera from healthy Japanese subjects were examined by the ordinary assay procedures using the calibration curves (fig 1) . In all cases values indicated that the a fetoprotein and ferritin concentrations were below 10 ng/ml and 200 ng/ml, respectively. These samples were then assayed by the proposed simultaneous assay method. As shown in fig 5, all samples gave absorbancy values at 500 nm under 0-015, which was evaluated as negative in this assay. In the proposed simultaneous assay system the cutoff points are set at 20 ng/ml of a fetoprotein and 200 ng/ml of ferritin. To 1000 obtain similar sensitivities at these concentrations, we added unlabelled anti-ferritin _, antibody to the EIA system. 4000
The intra-and interassay CVs of the proposed method are acceptable for the purpose of mass screening. As shown in table 1, a fetoprotein and ferritin concentrations below these cutoffpoints were classified as negative or ferritin suspicious. In practice, healthy subjects were classified as negative ( fig 5) . Therefore, most l high a sera classified as suspicious were considered to ml) and be positive. Thus subjects giving abnormal trations results were effectively differentiated from nor-.oposed mal subjects by the cutoff point (absorbancy: in fig 6 , 0*015).
hhigh oe As a tool for mass examination, the present out one assay system is not limited to the tumour -oncen-markers, but can be applied to any combination F point of markers, such as markers of inflammation, high a neonatal inborn defects, and microbial infec4o) with tated as others 
